US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
pharma · Hypertriglyceridemia · Asthma · GRCE
Grace Therapeutics
Grace Therapeutics drug portfolio — 37 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
3009, boul. de la Concorde E., Suite 102, Laval, Québec H7E 2B5, CA HQ
18 Employees
Public company Type
GRCE · NYSE Ticker
Company details
- Status
- Public
- HQ
- 3009, boul. de la Concorde E., Suite 102, Laval, Québec H7E 2B5, CA
- Employees
- 18
- Programs
- 29
- Drugs
- 37
- Patents
- 34
Grace Therapeutics pipeline
Portfolio lens on 37 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Grace Therapeutics drug portfolio — 37 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Grace Therapeutics in public FDA and regional records.
-
Development asset linked to Grace Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
benralizumab
Respiratory system (R03)US regulatory status: approved. Molecular target: Interleukin-5 receptor subunit alpha.
- Target
- Interleukin-5 receptor subunit alpha
- Mechanism
- Interleukin-5 receptor subunit alpha inhibitor
-
bupivacaine
Nervous system (N01)US regulatory status: approved. Molecular target: Sodium channel protein type 4 subunit alpha.
- Target
- Sodium channel protein type 4 subunit alpha
- Mechanism
- Sodium channel protein type IV alpha subunit blocker
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
US regulatory status: approved. Molecular target: 70S ribosome.
- Target
- 70S ribosome
- Mechanism
- 70S ribosome inhibitor
-
US regulatory status: approved. Molecular target: Aromatic-L-amino-acid decarboxylase.
- Target
- Aromatic-L-amino-acid decarboxylase
- Mechanism
- DOPA decarboxylase inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-2.
- Target
- Adrenergic receptor alpha-2
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
Development asset linked to Grace Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Serotonin transporter inhibitor
-
Development asset linked to Grace Therapeutics in public FDA and regional records.
-
Development asset linked to Grace Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glutamate [NMDA] receptor.
- Target
- Glutamate [NMDA] receptor
- Mechanism
- Glutamate [NMDA] receptor negative allosteric modulator
-
US regulatory status: approved. Molecular target: Mu-type opioid receptor.
- Target
- Mu-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
Development asset linked to Grace Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Grace Therapeutics in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
US regulatory status: approved. Molecular target: Mu-type opioid receptor.
- Target
- Mu-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
imiquimod
Dermatologicals (D06)US regulatory status: approved. Molecular target: Toll-like receptor 7.
- Target
- Toll-like receptor 7
- Mechanism
- Toll-like receptor 7 agonist
-
US regulatory status: approved. Molecular target: Glutamate [NMDA] receptor.
- Target
- Glutamate [NMDA] receptor
- Mechanism
- Glutamate [NMDA] receptor negative allosteric modulator
-
Development asset linked to Grace Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Adrenergic receptor alpha agonist.
- Mechanism
- Adrenergic receptor alpha agonist
-
US regulatory status: approved.
-
Development asset linked to Grace Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
Development asset linked to Grace Therapeutics in public FDA and regional records.
-
tirzepatide
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Gastric inhibitory polypeptide receptor.
- Target
- Gastric inhibitory polypeptide receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist
-
Development asset linked to Grace Therapeutics in public FDA and regional records.
-
Development asset linked to Grace Therapeutics in public FDA and regional records. Mechanism: Norepinephrine transporter inhibitor.
- Mechanism
- Norepinephrine transporter inhibitor
-
US regulatory status: approved.
-
zinc
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in Grace Therapeutics's portfolio. Mechanism: Blocks absorption of copper and induces the production of the copper-binding protein metallothionein..
- Mechanism
- Blocks absorption of copper and induces the production of the copper-binding protein metallothionein.